Orencia approved for polyarticular juvenile idiopathic arthritis

Orencia (abatacept) is now licensed for use in children aged 6 years and older in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) where there has been an insufficient response to other DMARDs including methotrexate.

The safety and efficacy of Orencia have not been evaluated in children under 6 years of age and, therefore, it is not licensed in this age range.

View Orencia drug record

Further information: BMS

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A person with blue-gloved hands uses a syringe to extract a dose of the Moderna COVID-19 vaccine from a vial.

Vaccine confirmed for autumn COVID-19 booster campaign

The new bivalent version of Spikevax, which targets...

A box of the Moderna COVID-19 vaccine with a vial of the vaccine standing in front of it.

Dual-strain COVID-19 vaccine approved by MHRA

An updated version of the Moderna COVID-19 vaccine,...

Boxes and bottles of medicines on shelves in a pharmacy dispensary.

Medicine shortages increasing, say GPs

Medicine shortages have worsened during the past year,...